Ramsay Health Care suspends dividend and raises capital

Ramsay Health Care Limited (ASX: RHC) shares are in a trading halt after the company announced a capital raising.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Shares in Australia's largest hospital operator Ramsay Health Care Limited (ASX: RHC) were placed in a trading halt earlier today, pending details of a capital raising.

Capital raising and dividend suspension

Ramsay is looking to undertake an equity raising worth up to $1.4 billion, consisting of $1.2 billion in an underwritten institutional placement of shares and $200 million in a non-underwritten share purchase plan.

The institutional placement will be conducted at $56.00, representing a 12.9% discount from Ramsay's last closing price of $64.29 and will see approximately 21.4 million new shares being issued. Following the completion of the placement, Ramsay will be looking to raise up to $200 million from retail shareholders through a share purchase plan.

In addition to the capital raising, Ramsay announced that due to the impact of the coronavirus pandemic on cash flow, the company has temporarily suspended payment of its ordinary share dividends. However, Ramsay did note that it will continue to pay dividends on its Convertible Adjustable Rate Equity Securities (CARES).

Why is Ramsay raising capital?

In an announcement to the market this morning, Ramsay cited that the suspension of elective procedures due to COVID-19 has led to an uncertain operating environment. As a result, the equity raising will provide Ramsay with financial flexibility and security in the current environment, whilst also allowing the company to take advantage of any future growth opportunities.

Ramsay has operations in more than 500 locations across 11 countries. As a result of the coronavirus pandemic, respective governments in each of Ramsay's major operating regions deferred elective procedures in private hospitals in order to support public health systems.

Last month, Ramsay withdrew its earnings guidance for FY20, citing the uncertain duration and impact of the coronavirus pandemic. With elective surgeries being the main source of revenue for private operators like Ramsay, the Australian government recently provided private hospitals with a $1.3 billion viability guarantee. However, with some elective surgeries being resumed, the income that private hospitals receive will reduce the funding flow from the government.

Should you buy?

Restrictions on elective and non-urgent surgeries will be partially lifted by the federal government on 27 April. As a result, post-cancer, hip, knee, and other joint replacement surgeries will be able to go ahead in addition to IVF procedures.

The Ramsay share price has tanked more than 20% from its high in mid-February of $80.93. Ramsay shares will remain in a trading halt until the commencement of normal trading on Thursday, 24 April 2020.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »